Literature DB >> 27155191

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.

V Mave1, A Chandanwale2, A Kinikar2, S Khadse2, A Kagal2, N Gupte1, N Suryavanshi2, S Nimkar2, H Koli2, S Khwaja2, R Bharadwaj2, S Joshi2, H Horng3, L Z Benet3, G Ramachandran4, K E Dooley5, A Gupta1, M Gandhi3.   

Abstract

Assessing treatment adherence and quantifying exposure to anti-tuberculosis drugs among children is challenging. We undertook a 'proof of concept' study to assess the drug concentrations of isoniazid (INH) in hair as a therapeutic drug monitoring tool. Children aged <12 years initiated on a thrice-weekly treatment regimen including INH (10 mg/kg) for newly diagnosed tuberculosis were enrolled. INH concentrations in hair were measured using liquid chromatography-tandem mass spectrometry at 1, 2, 4 and 6 months after initiating anti-tuberculosis treatment. We found that INH hair concentrations in all children on thrice-weekly INH were detectable and displayed variability across a dynamic range.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27155191      PMCID： PMC4889729          DOI： 10.5588/ijtld.15.0882

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  16 in total

1.  Hair as a biological specimen for therapeutic drug monitoring.

Authors:  J H Beumer; I J Bosman; R A Maes
Journal:  Int J Clin Pract       Date:  2001 Jul-Aug       Impact factor: 2.503

2.  Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Authors:  Jotam G Pasipanodya; Shashikant Srivastava; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

Review 3.  Pediatric tuberculosis: global overview and challenges.

Authors:  Soumya Swaminathan; Banu Rekha
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

Review 4.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment.

Authors:  Giovanni Sotgiu; Jan-Willem C Alffenaar; Rosella Centis; Lia D'Ambrosio; Antonio Spanevello; Andrea Piana; Giovanni Battista Migliori
Journal:  Int J Infect Dis       Date:  2015-03       Impact factor: 3.623

6.  Using Lopinavir Concentrations in Hair Samples to Assess Treatment Outcomes on Second-Line Regimens Among Asian Children.

Authors:  Wasana Prasitsuebsai; Stephen J Kerr; Khanh Huu Truong; Jintanat Ananworanich; Viet Chau Do; Lam Van Nguyen; Nia Kurniati; Pope Kosalaraksa; Tavitiya Sudjaritruk; Kulkanya Chokephaibulkit; Narukjaporn Thammajaruk; Thida Singtoroj; Sirinya Teeraananchai; Howard Horng; Peter Bacchetti; Monica Gandhi; Annette H Sohn
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-26       Impact factor: 2.205

Review 7.  Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms.

Authors:  Elena García-Martín
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

8.  A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.

Authors:  Monica Gandhi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Yong Huang; Kathryn Anastos; Mardge Cohen; Jack A Dehovitz; Gerald B Sharp; Stephen J Gange; Chenglong Liu; Susan C Hanson; Bradley Aouizerat
Journal:  J Infect Dis       Date:  2012-08-20       Impact factor: 5.226

9.  "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

Authors:  Thomas J Podsadecki; Bernard C Vrijens; Eric P Tousset; Richard A Rode; George J Hanna
Journal:  HIV Clin Trials       Date:  2008 Jul-Aug

10.  Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.

Authors:  Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Chengshi Jin; Audrey L French; Marla J Keller; Michael H Augenbraun; Stephen J Gange; Chenglong Liu; Wendy J Mack; Monica Gandhi
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240
View more
  2 in total

1.  Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.

Authors:  Vidya Mave; Aarti Kinikar; Anju Kagal; Smita Nimkar; Hari Koli; Sultanat Khwaja; Renu Bharadwaj; Roy Gerona; Anita Wen; Geetha Ramachandran; Hemanth Kumar; Peter Bacchetti; Kelly E Dooley; Nikhil Gupte; Amita Gupta; Monica Gandhi
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

2.  Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent M. tuberculosis infection in HIV-exposed uninfected children.

Authors:  Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jaclyn N Escudero; Thomas R Hawn; Grace C John-Stewart
Journal:  BMJ Open       Date:  2020-01-21       Impact factor: 2.692
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.